Date: 2014-08-05
Type of information: Commercialisation agreement
Compound: Iclusig® (ponatinib)
Company: Ariad Pharmaceuticals (USA - MA) Medison Pharma (Israel)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement:
Action mechanism: Iclusig® is a kinase inhibitor. The primary target for Iclusig is BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and Philadelphia -chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Iclusig was designed using ARIAD\'s computational and structure-based drug design platform specifically to inhibit the activity of BCR-ABL. Iclusig® targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation, which has been associated with resistance to other approved TKIs.
Disease: Philadelphia -positive (Ph+) leukemias
Details: * On August 5, 2014, Ariad Pharmaceuticals and Medison Pharma, Israel\'s leading international marketing group for innovative pharmaceuticals, announced that Ariad has granted Medison exclusive rights to commercialize Iclusig® (ponatinib) in Israel in patients with Philadelphia -positive (Ph+) leukemias. Under the terms of the agreement, Ariad Pharmaceuticals (Israel) Ltd will be the Marketing Authorization Holder (MAH) of Iclusig® in Israel , and Medison will be responsible for sales and marketing, medical affairs, regulatory support, as well as obtaining, in collaboration with Ariad, the pricing and reimbursement approval of Iclusig®. Ariad has submitted its Marketing Authorization Application for Iclusig® in Israel , which is currently under review with the Israel Ministry of Health . Marketing approval and commercial launch of Iclusig® are expected to occur in the second half of 2015.
Financial terms:
Latest news:
